Table 2

Progression-free and overall survival Cox regression analyses

CovariateUnivariate analysisMultivariate analysis
HR (95% CI)P valueHR (95% CI)P value
Progression-free survival
Age (continuous variable)1.01 (1.00 to 1.03)0.071.01 (0.99 to 1.03)0.26
Male gender1.14 (0.83 to 1.57)0.431.32 (0.94 to 1.86)0.11
Non-Hispanic white race/ethnicity1.03 (0.71 to 1.50)0.881.11 (0.76 to 1.63)0.59
Cancer type
 NSCLC 1.02 (0.72 to 1.45)0.911.13 (0.77 to 1.66)0.54
 Melanoma0.37 (0.21 to 0.67)<0.0010.39 (0.22 to 0.72)0.002
Anti-CTLA4 administered1.11 (0.69 to 1.42)0.661.80 (1.02 to 3.19)0.04
Concurrent/sequential therapy1.24 (0.89 to 1.74)0.211.13 (0.79 to 1.62)0.51
BMI≥250.69 (0.51 to 0.94)0.020.87 (0.59 to 1.28)0.48
Weight-based dose ICI0.96 (0.68 to 1.34)0.791.39 (0.80 to 2.42)0.24
BMI≥25/Weight-based dose interactionNANA0.53 (0.26 to 1.10)0.09
Overall survival
Age (continuous variable)1.02 (1.01 to 1.04)0.0041.02 (1.00 to 1.03)0.03
Male gender1.19 (0.88 to 1.62)0.261.41 (1.01 to 1.97)0.04
Non-Hispanic white race/ethnicity1.20 (0.83 to 1.72)0.331.34 (0.92 to 1.97)0.13
Cancer type
 NSCLC1.26 (0.89 to 1.79)0.191.26 (0.86 to 1.85)0.24
 Melanoma0.47 (0.27 to 0.81)0.0070.43 (0.24 to 0.77)0.004
Anti-CTLA4 administered1.00 (0.64 to 1.57)0.991.70 (1.01 to 2.88)0.05
Concurrent/sequential therapy1.16 (0.82 to 1.62)0.411.09 (0.76 to 1.57)0.64
BMI≥250.77 (0.57 to 1.04)0.080.96 (0.65 to 1.42)0.85
Weight-based dose ICI1.04 (0.75 to 1.44)0.811.57 (0.93 to 2.64)0.09
BMI≥25/Weight-based dose interactionNANA0.5 (0.25 to 0.99)0.05
  • BMI, body mass index; CTLA4, cytotoxic T lymphocyte antigen 4; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; NSCLC, non-small cell lung cancer.